Showing posts with label Francis Collins. Show all posts
Showing posts with label Francis Collins. Show all posts

Tuesday, September 7, 2010

The Gospel of St Francis....Collins, that is

The Sept 6 New Yorker has a story about Francis Collins, head of the National Institutes of Health -- his life, his religion, and how he thought he had resolved the debate over the use of embryonic stem cells.  He is, as everyone knows, a born-again evangelical Christian, so naturally people wondered where he would come down on this issue. He's often treated as if his word is Gospel when it comes to health; but he's not Catholic so he's not St Francis.

Indeed, people wondered how he'd come down on many issues, given his religious bent, but he assured us that this job was separate from his religion (he was quoted in the New York Times at the time of his nomination as saying, “I have made it clear that I have no religious agenda for the N.I.H.,” he said, “and I think the vast majority of scientists have been reassured by that and have moved on").  And indeed, his friends all assured us when he was appointed that he wouldn't let his religion guide his decisions about science.

Oh, really?  As the story in the New Yorker puts it, the way he made his decision about stem-cell research was to reconcile his views on stem cells with his Christian morality.  He ultimately decided he was in favor of embryonic stem cell research, but not before he wrestled with the decision from his religious point of view.
Before Collins had a direct say in the Administration’s decision on stem cells, he was personally torn by the ethical questions posed by stem-cell research. He has long opposed the creation of embryos for the purpose of research. He sees a human embryo as a potential life, though he thinks that it is not possible scientifically to settle precisely when life begins. But Collins also feels it is morally wasteful not to take advantage of the hundreds of thousands of embryos created for in-vitro fertilization that ultimately are disposed of anyway. These embryos are doomed, but they can help aid disease research.

Although his feelings about embryonic stem-cells are indeed pro-research, and satisfied scientists, particularly those doing stem cell research -- he was quoted as being 'stunned' by the legal decision two weeks ago to halt stem cell research -- it can't be denied that he filtered his thinking through his religious beliefs.  Just as those who were not in favor of his appointment worried that he would do -- and those who supported him assured us he wouldn't.  If he makes the 'right' decision based on his religious views, in the minds of scientists who want to be free to do whatever they want to do, is that now okay?

We all have a moral filter of some sort, and make decisions based on what we think is right and wrong, but one would hope that the head of the organization that guides the direction of research into fundamental life and death matters would have a more nuanced, less superstition-driven basis for those decisions.  Indeed, in his official position, with his hands on so much of the people's money, his decisions should be driven by what would have the greatest impact on the health of the most people.  We trust him when he says that he doesn't believe he has a religious agenda for the NIH, but when his basis for decisions is his evangelical faith, what else can you call it?

And, it must be said that our own primary concern when he was selected to head the NIH had more to do with his genetic and technology fundamentalism than his religion -- a concern that the New Yorker story doesn't acknowledge, though surely we weren't the only scientists who felt this way.  Dr Collins is a technophile's technophile, and there are many reasons to challenge the unrestrained investment in hypertechnologies as the main mission of our national heath institute.

Tuesday, August 17, 2010

Francis Collins, personalized genomic medicine, and the nature of probabilistic risk

Probability and the weather
Personalized forecasts
People regularly complain about the weather forecast in a way that misunderstands probability.  It's a sensitive subject for Ken, as a one-time meteorologist in a long-ago former life.  If the forecast is for a 30% chance of showers, and it stays dry, it's often viewed as a bad forecast.  You should have played golf after all.  If it rains, it's often viewed as a bad forecast.  Dammit, they ruined your golf outing, by driving you prematurely into the 19th hole bar!

Neither conclusion is right.

One can only really tell whether the forecast was right the next day, by totaling up the area that received rain, or by averaging the fraction of each area that received rain at any given time, or something like that.

The key point is that this is a 'personalized' forecast in the same way that genomic medicine, and Direct to Consumer (DTC) genetic risk estimation are personalized.  For a given genotype, or given golf course, whether it actually rains or not, or whether you get the disease in question, is almost irrelevant to whether the forecast was a good one.

Probability and risk of disease
Personalized genomics
We said on Saturday that Francis Collins reactions to his genotypic diagnosis of being at elevated risk for diabetes were, at his diabetes-free status at age 60, irrelevant to the genotype-testing result.  If the population average risk of diabetes is, say, 10%, that means 10% of the population will get the disease at some point in their lives.  If Francis' genotype-based relative risk is elevated by, say, 20% relative to  the risk of the average Joe, his absolute risk is raised to 12% (and we're exaggerating risks here to make the point, since most of the genotype-based  risks of common diseases add considerably less than 20% of the average lifetime relative risk, and most lifetime risks are less than 10%).

But in fact he doesn't have diabetes.  That says almost nothing about the accuracy or usefulness of his risk estimate.  12% risk means that 88% of people with the same genotype don't get diabetes, and his status is wholly consistent with that (or with his being at the average risk), and says nothing about whether the risk estimate was accurate.  The only risk estimate that should affect his behavior (he reports slimming down etc. in response to the genotype data), is the 'conditional' risk of getting diabetes at some future age, for a white male who has already survived until age 60.  That is probably an unknown value, for many reasons, such as lack of enough data.   Indeed even if the genetic risk estimate is accurate, a person with his genotype could, if diabetes-free at age 60, actually be at lower than average risk from his age onward.  Why?  Because the bulk of those who were born with the same genotype might already have gotten diabetes at a younger age: earlier onset is a typical way that elevated-risk genotypes work.

The issues are subtle, and just like weather forecasts, easy to misunderstand.  Another reason people should shun DTC services, and just adopt health lifestyles to the extent they can.

More profoundly, if Dr Collins is at our hypothetical 20%  relative risk, that means that the average person with his detected genotype is at 20% increased risk, but does not mean that everyone with that genotype is!  For example, those with the genotype who eat too much McFastfood may be at a 90% risk of diabetes, hugely elevated over the general population risk perhaps, while vegans with the same genotype could even be at lower risk than the population average.  We rarely know enough about interacting or confounding variables, like other genes or lifestyles, relative to the one we know about (the tested genotype) to say more than what's average for that genotype.  But we have every reason to believe that not everyone with the genotype is at its average risk.

When risk differences are less than huge in absolute terms, personalized medicine cannot judge the relevance of these issues except at best in a here-and-now population context, such as by a case-controls study, and these exposure contexts are always changing.  That's why it's important to understand what probabilistic predictions mean, when it comes both to your golfing decisions, and to your life.

In fact for most diseases if you want to know much, much more about your risk than any genotype service can tell you,  just look at the health history of your relatives. That's been known since Darwin's time.  And unlike DTC services, that information's free!  No doctor bills, no unnecessary testing, no specific genes need to be identified.  If we learn of specific gene-based therapies, and you're at high familial risk, then it would be worthwhile to have a proper genetic counseling service do the test.

A Snake Oil factor, but it cuts both ways
The DTC business is cowboy capitalism at this stage, and selling this kind of snake oil to people totally unable to understand the actual meaning of the data is an ethical as well as policy issue, and of course there is disagreement about where the ethical lines are where they should be drawn.  Even most doctors--even most geneticists--are helpless to understand the nature, accuracy, or stability of these risks.  Of course there is always a lot of selling going on, as a glance at Parade or an airline magazine will clearly show (shrink your prostate!  get rid of age wrinkles! have a 20 year-old body at age 70!).  As P T Barnum said, there's a sucker sitting in every airplane seat.  But this is why regulation is important, in our view, in something so closely involved with life, death, and health-care costs.

We've suggested in our posts that the FDA should treat this kind of DTC 'advice' as practicing medicine, and license it only as a part of genetic counseling where it could in principle be properly constrained and regulated to stick closer to truths that we can generally agree on and that consumers (and counselors and physicians) can make reliable sense of.

However we must admit that this is partly a political stance by us.  If the entire business were just shifted to medical clinics, the same testing would probably take place, with the same level of understanding.  After all, the issues are complex even for those with sophisticated knowledge.

In fact, transferring the business (doubtlessly to be supplied, probably on a larger scale, by the same companies) and perhaps establishing it part of what would be lobbied into routine medical exams, the genomic testing could be much more costly to the health-care system, and more lucrative for the companies in the future, and hence perhaps even more problematic than it is now.  Still, we think regulation is better than caveat emptor.

Bottom line?
So the simple conclusion for us is that it's best to follow advice we've only known since Hippocrates a mere 2400 years ago (moderation in all things), and skip both that extra dessert and the personalized DTC genotyping.

Monday, June 14, 2010

The Fired Coach Syndrome

The Fired Coach Gets Hired Again
Well, sports fans, you probably are all familiar with the Fired Coach Syndrome. That's the regular pattern whereby, when a coach is fired because his team doesn't win--even if it's because they haven't got good enough players--he is immediately hired by some other team and treated as their savior. We need not name names, because as one coach said, all coaches have either been fired, or will be fired (with the single exception of our own Joe Paterno, shown at left!).

What has this got to do with genetics, evolution, or any other MT theme? The NY Times has a story--a front page story--on the failure of genome-wide association studies (GWAS) to lead to many disease 'cures'. Big news!

Or is it?

This story is by an op-ed writer who has built his career over many years by serving as a notorious mouthpiece for the genomics 'industry'. Now, without a whiff of contrition, he's telling a new tale, and again making a Big Story of it. But, as before, he does it uncritically, too.

Genomewide Association Studies
It's true that countless millions have been spent on GWAS with little of the long-promised 'cures' to show for it. A few of us have been long-term critics of this approach, for the decade in question, and for legitimate reasons. Complex traits are here today because whatever their genetic basis, it passed the sieve of evolution. For human geneticists, the main interest has of course been the genetic basis of disease, for obvious societal and funding reasons.

But for many decades it has been clear that while genes contribute substantially to their variation, these traits (normal or otherwise) are basically not due mainly to single genetic effects. The evolutionary assumptions that are implicit in complex disease mapping studies never, except for wishful thinking, predicted other than what we have seen. And another fact that the NYT story and a recent journal article or two report as curious--that we can predict risk better with a patient's family history than with his/her genotype data--is entirely expected, based on reasons that everyone properly trained in genetics should have known (for approximately the last 100 years based on the genetics of 'polygenic' traits).

The Evolution of Complexity
Evolution generates redundancies, removes nasty variants, and generates a distribution of mutation effects and allele (genetic variant) frequencies that will not as a rule lead to common, chronic, late-onset, or complex traits being caused by just a gene or two (and here we're not eve considering the wild card, the environmental effects that are usually substantially more important than the genetic ones). But that doesn't mean there would be no identifiable contributing genes: for most traits some alleles, in some genes, in some populations, will have marked effects. Unlike a complete 'bust', that, too, is what we find and was predictable.

From countless GWAS and other approaches to enumerate the genetic cause of complex traits, we know of a large number of contributing genes, say around 1000. But only a surprising few of these do so replicably or with high probability and nontrivial frequency. What we see today is what everyone should have known to expect and a few of us were saying this in papers at the beginning of the decade in question.

Selling the Brooklyn Bridge--Again
So if there's no news in this news, why does the former hawker for the vested genomic interests now have the creds to write as if insightfully about the current state of affairs? It's by consulting the very people who, mainly knowingly, lobbied and hyped everyone into the GWAS era. Why should he be getting assessments of the situation from those whose mouthpiece he was for an approach that didn't work, and for predicted reasons? The same vested interests are now advocating their new grand theories, such as that finally we'll solve the problem in terms of (take your pick) copy number variation, epigenetics, whole genome sequences, large biobanks, many very rare alleles with strong effect, combinations of common alleles with modest, effects, etc.

Why should those who sold us the old Brooklyn Bridge be listened to when they advocate these new ideas which, not incidentally, require larger, longer, more costly studies (for their own labs?). They are not giving us reasons, just hand-waving invocation of current fads or Plan B's. Naturally, they like the idea of locking in funding for the rest of their careers. But would people have any interest at all in buying this new Brooklyn Bridge?

The FCS
The answer is the Fired Coach Syndrome. Somehow, we tend to believe that these people with known rap sheets are still the experts. Their past statements and advocacy are not taken to be the lobbying that they actually were. Now, they're being listened to as the coaches of the new Team GenomeSequence.

But there are deeper and more serious issues. Unfortunately, they are reflected in the latest Big Story now being marketed in this Times article and elsewhere, which continues to suffer from uncritical hyperbole and oversimplification.

We Already Knew All This
The fact is that after a few GWAS (and other kinds of studies of variation underlying single-gene traits), many years ago, we confirmed the theory we had about evolution and complex genetics (which goes back nearly 100 years). We should have declared our knowledge firm, and thought of better ways to understand complex traits. But too many vested interests, without better ideas, demanded the big GWAS funding. In that sense GWAS and its fellow-travelers have generally been a very expensive bust.

But here we have to again criticize the attempt to make this a new Big Story. Because we have learned a lot, even if at great cost, about genetic control. Huge and useful data bases have been created. Technology has been developed. DNA sequencing is now about as cheap as your HDTV set. Many corporations have flourished--money for their stockholders, and jobs for employees. Much has been learned about genomes of many species, and their variation. Despite private greed, much or most of these data are freely available to anyone. Genetics has flourished perhaps like no science ever before.

Maybe the funds should have been spent in other ways, but they have led to much new knowledge. This doesn't mean that 1000 new promising targets for Pharma have been revealed, as Francis Collins and Eric Lander enthusiastically claim: instead, most of those genes are trivial contributors. Still, these investigators have sponsored or done technically excellent work, contributed to the huge public data bases, new understanding of genomic functions of many kinds. They've done this while, largely unrecognized even by themselves, showing that classical theory was right--and that is a substantial baby in the bathwater.

There are important questions about complex causation, which science can address, especially if we could decide to confront complexity on its own terms rather than promising to reduce it to a manageable number of enumerable causes as has been done to date and is essentially still being done.

However, the reportage errors continue: Despite the waste and the catering to vested political interests, the Times article's main claim to Big Story, the fact that we haven't developed many 'cures' of complex disease, is irrelevant to whether GWAS was a scientific success.

Disease is complex, organisms evolved to resist tinkering from the outside--especially tinkering with our genomes--and attacking diseases genetically is a difficult engineering feat. Whether, when, or how that will be done successfully is not yet clear, but nobody has any right to expect it to be rapid. It's a bum rap at GWAS to say they failed because the gene engineers haven't yet figured out how to use the results to make cures. The real rap, and what should discredit much of the hype machine, is that they have promised 'cures' (in fact, and to be fair, some of the main advocates--though not Francis Collins--have at least been slightly circumspect, warning this is all for our grandchildren or beyond--even if such caveats were declared in passing and did not temper their lobbying for the GWAS and related resources).

Bigger, Longer, Pricier More-of-the-same
However, the Failed Coach Syndrome would suggest that we should be very skeptical about the same writers and scientists who are now deftly expostulating their latest grand theories, paradigm shifts, and new strategies. Because they're largely rationales for more-of-the-same, except at larger scale, longer time frames, and greater cost. What we should be doing is understanding where the baby is, and not just fostering existing self-interest by saying there was no baby in the bath so let's run a lot more bathwater and maybe we'll find triplets in there someplace.

One thing that some are advocating is to search genomewide sequence data from patients, to find clearly harmful mutations in functional genome regions that are known to be related to the physiology in question--such as rare 'knockout' mutations in those genes which might be inferred to be causal and then tested experimentally. Whether this justifies the continued use of mega-scale genomic approaches is debatable. Though one can predict there will not be a huge bonanza of findings with much therapeutic value, there certainly will be some, and at least to some extent this genome-screening approach is very different from the statistical-evolutionary basis underlying GWAS. The reason is too complex for this post, but the gist is that such studies will finally rest on biology rather than baloney, even if it's already being over-sold in the usual lobbying way.

Today's PT Barnums
As to Fired Coaches, it must be said that high level expertise and capability is not to be found everywhere, and our genetic PT Barnums got there largely because of both management and scientific skill. Once the research community has its hands on funds, and labs have been built, it's politically difficult if not impossible to shift from this entrenchment to new investigators or unrelated approaches. Science is part of society and works by evolution, which includes careerism. Scientific revolutions can't be ordered up by the media or by funding institutions with their turf-protecting bureaucrats: they just happen when and where they happen. So in that sense we must in practice rely on the same cast of characters, though whether we should try to move gradually away to fresh approaches is a legitimate question.

In science, we should at least be aware of what's afoot because otherwise resources continue to be diverted for less rather than more effective use. But can we learn to temper our claims--or at least penalize those who don't? Or can the system demand accountability for results if we promise them? Or can we establish full-stop criteria for large projects once it's clear that they aren't really bearing fruit? Probably not. Because the real name of the game is getting funding. To a substantial extent, scientific facts themselves are secondary. That's the anthropological truth. Or perhaps, as Marshal McLuhan said decades ago, in modern science the medium really is the message. And now we are clearly going to hire the same coaches to guide us into the future!

Maybe we have no choice. But we should be aware that's what we're doing. And if you believe their new pronouncements or their media megaphones, then we have a bridge that we'd like to sell you. And, by the way, Joe Paterno has stayed in the national rankings and just signed a new contract....at age 83.

Tuesday, April 6, 2010

The efficacy of predicting gene prediction

Francis Collins has a track record of predicting tremendous advances in health from the human genome project --what he and many others said would be a revolution. Writing in the April 1 issue of Nature, which celebrates the 10th Anniversary of the Human Genome, he asks if the revolution that he and others foresaw more than a decade ago has now arrived. He writes that he never deletes a powerpoint file, so he knows exactly what he predicted when he stood on the podium with President Clinton in 2001 and announced the completion of the human genome sequence.
Predictive genetic tests will be available for a dozen conditions
Interventions to reduce risk will be available for several of these
Many primary-care providers will begin to practise genetic medicine
Preimplantation genetic diagnosis will be widely available, and its limits will be fiercely debated
A ban on genetic discrimination will be in place in the United States
Access to genetic medicine will remain inequitable, especially in the developing world
He says that it's fair to say that these predictions have come true. Well, yes, one can always declare victory after the fact. He also adds, "The promise of a revolution in human health remains quite real."  


But let's look at his predictions one at a time.  In fact, there are dozens of predictive genetic tests available -- but how accurate are they? Interventions to reduce risk of, say, obesity or type II diabetes are available, yes, but they've been known for decades, if not centuries -- diet and exercise. What he means by genetic medicine isn't really clear, and preimplantation genetic diagnosis can't be claimed to be due to HGP, but to technological advances, as well as the discovery of diseases for pediatric Mendelian diseases, which was already being done before the human genome sequence. A ban on genetic discrimination is in place (GINA), but how successful that will be is still an open question (and, as our friend, geneticist and tuba player Joe Terwilliger says, the differential rates 18 year old boys and girls pay for car insurance is genetic discrimination, isn't it?). And, well, predicting differential access to anything medical based on income disparities isn't exactly a challenge.


Collins in fact made many other predictions (or promises) for the HGP, particularly in the late 1990s as the human genome was nearing completion. For example, in a lecture he delivered in 1999 he presented a scenario for the year 2010 whereby a hypothetical young man, a smoker, is found to have high cholesterol. Here's a bit of that imagined scenario:
Aided by an interactive computer program that takes John's family history, his physician notes that there is a strong paternal history of myocardial infarction and that John's father died at the age of 48 years.
To obtain more precise information about his risks of contracting coronary artery disease and other illnesses in the future, John agrees to consider a battery of genetic tests that are available in 2010.  After working through an interactive computer program that explains the benefits and risks of such tests, John agrees (and signs informed consent) to undergo 15 genetic tests that provide risk information for illnesses for which preventive strategies are available.
John is please to learn that genetic testing does not always give bad news -- his risks of contracting prostate cancer and Alzheimer's disease are reduced, because he carries low-risk variants of the several genes known in 2010 to contribute to these illnesses. But John is sobered by the evidence of his increased risks of contracting coronary artery disease, colon cancer, and lung cancer. Confronted with the reality of his own genetic data, he arrives at that crucial "teachable moment" when a lifelong change in health-related behavior, focused on reducing specific risks, is possible. And there is much to offer. By 2010, the field of pharmacogenomics has blossomed, and a prophylactic drug regimen based on the knowledge of John's personal genetic data can be precisely prescribed to reduce his cholesterol level and the risk of coronary artery disease to normal levels...
Understandably, Collins was a great cheerleader for the genome project. But that is exactly the problem, and we regularly write about it: the life-as-lobbying worldview. Dr Collins did say that he believed that diseases would turn out to be caused by numerous genes with small effects, interacting with environmental factors, but he clearly believed that these genes would be common and identifiable (hence, the HapMap project, whose scenarios and promises did not materialize except by a lot of post hoc wriggling and redefinitions, such as of 'common').  And he clearly believed that understanding genetic effects would be straightforward -- and counteractable, with some help from the pharmaceutical industry.


In fact, the 'several genes' he predicted would be found by 2010 to be responsible for Alzheimer's disease turn out to be hundreds of genes, each with many alleles and mostly with tiny effects. And, although he did write that lifestyle changes were a component of prevention, and that John should quit smoking, he also clearly believed that designing prophylactic drugs based on what was learned from the human genome would be so easy that by the year 2010 we'd be able to prevent many genetic diseases pharmaceutically. After we easily predicted them.


But in fairness, no one should be strictly held to their predictions (well, except for seers and grant seekers who promise too much) and mostly this hypothetical scenario is interesting as insight into Collins' beliefs about the importance of genes and the power of technology to counteract them -- a set of beliefs that still drives him as director of the NIH, which we have blogged about before. But to us, at least as interesting is something we wrote about last week, the use of modern technology to tell us something we already know. In Collins' hypothetical scenario -- which was completely made up; remember, he could have imagined anything -- John learns from his genetic testing that he was at risk of heart disease and colon cancer. But his family history already told him that! This isn't exactly something that justifies the billions of dollars spent on the HGP!


As director of the National Institutes of Health and past director of the National Human Genome Research Institute, Collins had, and continues to have, tremendous influence over the direction of medical research funding for the last decade, and into the foreseeable future. Indeed, as we've said many times before, his faith-based commitment to improving our health through genetics and technology is taking real money away from real problems that could have real solutions, given equal commitment to solving them. 

Monday, January 4, 2010

Healthy People or unhealthy promotions?

Leading Health Indicators
Healthy People 2010? A story is making the rounds (e.g., here) about how well or how poorly the US has met goals set in 2000 for improving the health of its population by 2010. Not so well, by most measures, though there have been some improvements (some, in spite of ourselves -- heart disease mortality tends to go up or down without our understanding why).
There are more obese Americans than a decade ago, not fewer. They eat more salt and fat, not less. More of them have high blood pressure. More U.S. children have untreated tooth decay.
But the country has made at least some progress on many other goals. Vaccination rates improved. Most workplace injuries are down. And deaths rates from stroke, cancer and heart disease are all dropping.

As a new decade approaches, the government is analyzing how well the U.S. met its 2010 goals and drawing up a new set of goals for 2020 expected to be more numerous and - perhaps - less ambitious.
Why is meeting these goals so difficult?

The government uses 'leading health indicators' to measure the health of the population. These indicators are:
  • Physical Activity
  • Overweight and Obesity
  • Tobacco Use
  • Substance Abuse
  • Responsible Sexual Behavior
  • Mental Health
  • Injury and Violence
  • Environmental Quality
  • Immunization
  • Access to Health Care

Healthy people and the NIH
Note that, except for the goals that require political action, this is primarily a list that can only be accomplished by getting people to change their behavior. Which is interesting, since Francis Collins set five goals for the NIH when he took over the directorship last year, and which he reiterates in this week's Science, none of which have anything to do with changing behavior, and everything to do with high-tech research (he does include the goal of increasing access to health care, but it's clear from the mixed, at best, results of Healthy People 2010 that there isn't a straight line between health care and health). He begins his Science essay with this:
The mission of the National Institutes of Health (NIH) is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and to reduce the burdens of illness and disability.
Collins sounds as though the mission of the NIH is in accord with the Healthy People 2010 (and now 2020) goals set by the Office of Disease Prevention and Health Promotion, and the US Dept of Health and Human Services, but if they were really on the same page, he'd have put health education first and foremost in his list of priorities for the NIH. Or, Healthy People 2020 would include goals like Sequence everyone's individual genome, or biome, or nutriome, which big science, with Collins at the political forefront, has been promising for years will work miracles for our health.



To put it politely, Collins' goals remain wishful thinking with respect to health benefits, but a big boon for big science. We could generate more healthy years for more people, by far, by changing lifestyle exposures than we ever could by all the 'basic research' and genetics one can dream of. And this is not just keeping an old car running rather than inventing better cars: healthful lifestyles will work every generation.

Technocracy welfare
Dr Collins is instead a sales agent for our technocracy welfare system (of which we personally, it must be acknowledged, are beneficiaries), in the form of largesse from Congress. In fairness, one of his priorities includes focusing more on global health, which is laudable, especially for someone who has been a medical missionary in Africa, and it's very easy to argue that improving the health of people living in poor and underserved countries is good for the US as well, because extremely drug resistant TB doesn't stop at borders. But, most global health issues are understood, and we could go a long way toward solving them with money, infrastructure development and public health measures, which will help a lot more people a lot faster than high tech research.

But, issues with the NIH aside, if the "Healthy People 20whenever" goals are so clear, and could be met if only people would change their behavior, why isn't that happening? Because figuring out how to get health education to actually work is a long-standing challenge for public health. It is not rocket science and health policy should not be turned into rocket science.  But it is difficult, which you might think is perhaps a little odd, since advertisers seem to have no problem getting people to buy sexy cars, or supersize their fries. Why can't advertising be just as effective when it comes to health-related behaviors? Well, health-related behaviors that improve health, since supersized fries is health-related.

The facile answer is that advertisers sell fun stuff, while public health tries to sell restraint, moderation, eliminating the fun stuff. It's hard to do.

Reality checks
It's good to have goals. An organization needs goals. But, when the goals are so often much loftier than what can be accomplished, the organization needs to stop and think about why they've overshot, and what can be done about it.

There are three reality checks here. First, the taxpayers footing today's technocracy bill are not generally going to benefit from the work of no-matter-how-many DNA sequencers crunching. Those who do have serious genetic problems that can be understood in other ways, will hopefully benefit, even if that's years of hard work away. But cheaper ways to actually increase health--the behaviors mentioned above--exist and the same funds (and policy changes) could be put to those ends. They will, if adopted, pay off for as many generations as current technology promoters promise.

Second, these NIH programs are largely costly self-promotion. Without doubt there is a lot of good research done within, and paid for by, the NIH. And a lot of it is technological in ways that are fully justifiable. But it's embedded in huge amounts of self-protecting bureaucracy and baloney.

Nobody seriously could think that we would have 'Healthy People 2010' (unless we really hurry up!). This is advertising, but not of the health improvement kind.  It's spending money where it shouldn't be spent, primarily fostering scientists rather than taxpayers. It is cynically cruel to make grandiose promises that cannot be kept. It's reminiscent of the old communist countries' Five Year Plans that we so routinely ridiculed. We can do better. We can try more sincerely. And we can be accountable for what we boast about.  Note that the goals for Healthy People 2020 are going to be 'less ambitious.' 

Third, a minor point....or is it? Francis Collins says he believes in a personal God, roughly the fundamentalist Christian God. If that's the case, and if those who live virtuous temporary lives here on Earth will have eternal rewards in the Hereafter, then why on earth is it important to pour money into future technological solutions rather than to save the quality of life of those who are here right now, so they can live in faith and do good, rather than suffer in privation?

Well, leaving the last bit aside, the point here is to take with a grain of salt the advertising and hyperbole. If pure science and the fun of its practice are the purpose of research money, then let's just say so--this is about us and our careers--and stop pretending this is all about health per se. There have been major improvements in some areas of health, and technology (including genetics) has clearly played a role. But overall it's hard to argue that we're happier, or healthier, than we were before pouring billions into a lot of things we've been pouring billions into, things we know very well (as we've opined in numerous posts) are not bearing much fruit from the Tree of Life.

Thursday, August 20, 2009

Francis Collins announces his agenda

There's a report in this week's Nature of Francis Collin's announced agenda for the NIH ("Collins sets out his vision for the NIH", Elie Dolgin, Nature, published online August 18, 2009). Collins has defined five areas of 'special opportunity':

Collins, who headed the National Human Genome Research Institute in Bethesda from 1993 to 2008, made the case that investment in biomedical research creates jobs and offers quick economic returns. Looking ahead, he said that the agency should devote more money to "five areas of special opportunity". First, to applying high-throughput technologies in genomics and nanotechnology to discover the genetic bases of diseases including cancer, autism, diabetes and neurodegenerative disorders. Second, to developing diagnostics, preventative strategies and therapeutic tools through more public–private partnerships. Third, to reining in the costs of health care with comparative-effectiveness research and personalized medicine. Fourth, to expanding research into diseases affecting the developing world. Finally, to increasing budgets and investing in training and peer review to achieve a predictable funding trajectory for the research community.

So, this answers the question we posed here and here about how much emphasis Collins will give to genetics -- it's not a surprise that his first priority is genetics and technology, as his lenses are made of DNA. But, it also answers another question we posed about whether he will also emphasize health issues related to poverty, and apparently neglected diseases are on his agenda as well.

That's a good thing. Francis also tried to reassure those who had raised questions about his religious beliefs. Since he is a master at convincing Congress to give him more (and then more) money, and since he identifies a range of appropriate projects, it seems very unlikely that religion will be any sort of problem or issue with his leadership of NIH.

It's easier to predict now how skewed toward genetics his agenda will be. He is a firm believer in the molecular approach to disease not just that genetic mechanisms are involved in disease--which they surely are, in essentially all except trauma and lightning strikes, but also that natural variation in genotypes is a major factor in variation in individual disease occurrence.

It's this that we think is questionable, especially in regard to the common diseases that are mostly, and manifestly more affected by environments than by genotypes. It's clear that a lot of money will be spent, and we think wasted, on 'personalized genomic medicine' in relation to these disorders. Indeed, he has a book coming out next year on personalized medicine.

Meanwhile, many diseases, and small subsets of almost all diseases, truly are genetic in that the variation hugely increases risk that is only affected by lifestyle factors in minor ways. We think that the best way to invest in genetics is to mount an appropriately genetic assault on these. Hopefully he'll see that that is done.

But, he'll be an effective advocate for the NIH, and one has to wish him well, especially if he works to help implement universal health care.

Thursday, August 6, 2009

John Hawks invades our blog!

Thanks for the mention, John. We appreciate it. Though, the link that sent John here misrepresents us a bit. Lisa Miller, writing in Newsweek in support of the Francis Collins appointment to head NIH , says
On a blog, anthropologist Kenneth M. Weiss complained recently that as Human Genome Project director, Collins "directly or indirectly intimidated other NIH agencies to get into the genome game … That did, and still does, co-opt funds that could be used for other things instead." The concern of some scientists, in other words, has nothing to do with religion. It's that his view of legitimate science doesn't extend to them.
No, the concerns are two. First, it is in the nature of bureaucrats to go for what they think will protect their portfolios, and that often if not usually means following the latest fads and fashions. It is not that genetics and genomics are unimportant, but that they had momentum and that attracts 'me-too' ers. It is certainly debatable whether committing so much money and energy to genetics was the best way that funds could or should have been spent to the extent they were.

Secondly, it's a problem when, if you've got a hammer, everything looks like a nail. These days everything looks like a gene. As regular readers of this blog know, our view has been that not everything is genetic, and yet genetics has had a growing or even predatory corner on research funds in the last few decades, largely due to Collins' prowess at convincing Congress of the importance of genes in explaining, preventing, and curing disease. That prowess will serve him well at the NIH, but his faith in genes, perhaps more disturbing than his faith in a personal god, is less likely to serve the rest of us as well.

We know, for example, that the health disparities in this country, not to mention the world, have almost zero to do with genetic susceptibility (except that which all humans share), and more to do with life styles, nutrition, infectious disease prevention etc. Most of the common diseases which our flesh is heir to can be prevented or delayed by lifestyle changes. If that were done, which should (we think) be Priority One at NIH, then the residuum of those diseases would be the cases that really are genetic.

Lifestyle changes are hard to mandate and research on relevant social behavior has failed us. Whether it's worth investing in that kind of research is a separate, debatable, question. Short of outlawing McDonald's and television, Americans probably would rather be fat and out of shape. Many of our fellow citizens still smoke, after all.

We have many reservations about the way things are being done in genetics and genomics these days, relative to the problems we know are 'out there', which are separate from the relative priority issue. We think very large amounts of funds are being spent to maintain the status quo even when we know it is not working. That's another way that systems, of all sorts, resist change. It is not a view against genetics, but one that would see genetics done in a better way, and one more relevant to the state purpose of health-research funds.

If Dr Collins takes a broader view of health rather than health research, as NIH Director, he may use his administrative skills to make excellent contributions to our country's and the world's well-being. But if his presence just encourages every university seeking grants and grant overhead, and so on, to continue to go for the gene, even if Dr Collins doesn't explicitly push them to do that, then his stint may be less sanguine. Time will tell.

Friday, July 17, 2009

Francis Collins and the NIH

Francis Collins, long-time director of the US National Human Genome Research Institute (part of our National Institutes of Health), is reported to be President Obama's choice to be the next NIH director. This is a curious choice and it is receiving comment from both Nature and Science this week (not to mention many blogs), and for good reasons.

First, on the surface it suggests a complete and total victory for the genetic view of life. That might have been fine for the Genome Institute, but seems much less so for NIH overall, because many if not most problems in both medicine and public health are not about genes or genetic variation (though they involve them at least indirectly) but are about environments, many kinds of therapies, prevention, and so on. One doesn't have to ignore the fact that genetics is certainly fundamental to life, and that molecular biology will become increasingly important, to know that (for example) most common diseases have little to do with genetic variation in any sensible way. Forcing things through a genetic conceptual lens will distort them, and root them in glamorous technology rather than concept or accountability for results.

As director of NHGRI, Dr Collins did a lot of things that can be praised and others that can be criticized. First and foremost among the former, perhaps, are that he nobly and successfully struggled to keep genome sequence and variation data in the public domain. But he also directly or indirectly intimidated other NIH agencies to get into the genome game, or even to contribute to NHGRI efforts. That did, and still does, coopt funds that could be used for other things instead. Partly, Francis rode a fashion, partly an explosion of genuinely new and important knowledge, and partly the Washington money game.

The other issue is Dr Collins' brand of Christian fundamentalism. He says he had a conversion experience, and believes in a 'personal' God and he's written a book about it. In the US context, that has implications for policy, not all of them good (and not all of them Constitutional, perhaps). He has done medical missionary work in Africa, as we understand it, but we don't know what kind of missionary work. If it was out in the sweaty hinterlands where people really need help, then he deserves and should get all the praise that is available for being consistent with the basic Christian principles that not all Christians follow (to say the least).

But a personal God intervenes in the world, and that is inconsistent with all the precepts of science. For example, one never expects experiments to be affected by God (or by prayer). Does he, or should we, pray for God to cure a loved one's disease? Science rests on the assumption that the world is a strictly material place to be understood in terms of its universal laws (like gravity, chemistry, etc.). And Dr. Collins clearly asserts that religions should basically not make scriptural claims about the world, because science will show that they are wrong. But what, then, is a personal God? These seem like incompatible views, which can be worrisome for someone in a position of science leadership in our culturally cloven society.

And what about evolution? What are his views of human origins, and the genetic relationships we bear with other species? Was that process mechanical, or God-directed? It makes a difference in how we interpret our own variation (not to mention racial variation), the differential impact of the 'curse' of disease, and the relevance of animal models. If humans are not 'just' genes, is that because God made us unique? If so, should we be licensed to torture animals in research? We do have to say that the NHGRI did not get involved in religious entanglements during Dr Collins' stewardship, but it is certainly fair to ask these things, as they have potential policy implications--especially if a fundamentalist chunk of the country will expect it.

Like grilling of a prospective Supreme Court justice, one would like to know how all our health needs will be addressed, not just one particular component of them. That will be of interest to those who are not just in genetics. Likewise, the religious aspect of Dr Collins' life is at least potentially relevant in our society, especially because genetics is inextricably and properly understood in the context of evolution; regardless of his view on evolution, religious literalists may expect him to use religion to filter research and policy decisions.

Supreme Court justices sometimes play the political role desired by those who appointed them, which is a shame since courts should be as objective as possible in the realities of human society. But sometimes they surprise. Dr Collins could go either way -- who can say? He could use his Christian religious beliefs to foster all sorts of health improvements for the needy here and abroad, rather than (as most genetics does) for the privileged. He could help international medical services (like Doctors Without Borders), a kind of US contribution to a medical Peace Corps. Or, he could stay close to his genetics worldview, narrowing the field directly or by bureaucrats being intimidated or chameleon-like in their struggle for cuts of the NIH pie.

In fact, there is no danger whatever that genetics research is going to be neglected; there are far too many commercial, academic, and bureaucratic careers that depend on it. We need to support basic genetics, but, for cost reasons, that should be done through NSF not NIH. But if anything is to be neglected it would be the work on the therapeutic approaches to hundreds of truly, seriously genetic diseases, and much less on the huge genomics studies aimed at genetic prediction or common diseases (like the targets of GWAS and biobanks); those are public-health scale approaches yet quart size Cokes and fries, not genes, are the major public health problems.

How Dr Collins will do will be interesting to see.